drugset / Trial / NCT06708663

HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours

NCT06708663

Phase 1/2 Recruiting 124 enrolled Hangzhou Hanx Biopharmaceuticals, Ltd.
NaSingle-groupOpen-labelTreatment

Summary

Phase IIa study of HX009+ IN10018 in combination with or without standard chemotherapy in patients with advanced solid tumours including biliary tract malignancies and malignant melanoma

Timeline

Start
2025-01-17
Primary completion
2027-12-31
Completion
2028-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject HX009 Protein / enzyme biologic 7.5 mg/kg
Subject HX009 Protein / enzyme biologic 10 mg/kg
Subject Ifebemtinib Small molecule 100 mg